Metal-dependent inhibition of HIV-1 integrase by β-diketo acids and resistance of the soluble double-mutant (F185K/C280S)

Molecular Pharmacology

Volumn 64, Issue 3, 2003, Pages 600-609

  Marchand, Christophe ^a   Johnson, Allison A ^a   Karki, Rajeshri G ^b   Pais, Godwin C G ^b   Zhang, Xuechun ^b   Cowansage, Kiriana ^a   Patel, Tapan A ^a   Nicklaus, Marc C ^b   Burke Jr , Terrence R ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DIKETO ACID; CARBOXYLIC ACID DERIVATIVE; INTEGRASE; METAL; OXOACID; RNA DIRECTED DNA POLYMERASE INHIBITOR; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CATALYSIS; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DNA BINDING; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVE SITE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; PRIORITY JOURNAL; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME;

ACETOACETATES; AMINO ACID SUBSTITUTION; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; MAGNESIUM; MANGANESE; MUTATION; PROTEIN BINDING; SOLUBILITY;

EID: 0041353616     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.3.600     Document Type: Article

References (59)

1. Allen FH and Kennard O (1993) Three-D search and research using the Cambridge Structural Database. Chem Design Automation News 8:1, 31-37.
2. Bao KK, Wang H, Miller JK, Erie DA, Skalka AM, and Wong I (2003) Functional oligomeric state of avian sarcoma virus integrase. J Biol Chem 278:1323-1327.
3. Billich A (2003) S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs 4:206-209.
4. Bischerour J, Leh H, Deprez E, Brochon JC, and Mouscadet JF (2003) Disulfide-linked integrase oligomers involving c280 residues are formed in vitro and in vivo but are not essential for human immunodeficiency virus replication. J Virol 77:135-141.
5. Bock CW, Kaufman Katz A, Markham GD, and Glusker JP (1999) Manganese as a replacement for magnesium and zinc: functional comparison of the divalent ions. J Am Chem Soc 121:7360-7372.
6. Bowerman B, Brown PO, Bishop JM, and Varmus HE (1989) A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev 3:469-478.
7. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, and Karplus M (1983) CHARMM: a program for macromolecular energy, minimization and dynamics calculations. J Comput Chem 4:187-217.
8. Brown PO (1998) Integration, in Retroviruses (Coffin JM, Hughes SH and Varmus HE eds) pp 161-203, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
9. Cai M, Zheng R, Caffrey M, Craigie R, Clore GM, and Gronenborn AM (1997) Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol 4:567-577.
10. Chen JC, Krucinski J, Miercke LJ, Finer-Moore JS, Tang AH, Leavitt AD, and Stroud RM (2000a) Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci USA 97:8233-8238.
11. Chen Z, Yan Y, Munshi S, Li Y, Zugay-Murphy J, Xu B, Witmer M, Felock P, Wolfe A, Sardana V, et al. (2000b) X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293) - an initial glance of the viral DNA binding platform. J Mol Biol 296:521-533.
12. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, De Clercq E, and Debyser Z (2003) HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 278:372-381.
13. De Clercq E (2001) New developments in anti-HIV chemotherapy. Curr Med Chem 8:1543-1572.
14. Deprez E, Tauc P, Leh H, Mouscadet JF, Auclair C, and Brochon JC (2000) Oligomeric states of the HIV-1 integrase as measured by time-resolved fluorescence anisotropy. Biochemistry 39:9275-9284.
15. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, and Davies DR (1994) Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science (Wash DC) 266:1981-1986.
16. Engelman A and Craigie R (1992) Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol 66:6361-6369.
17. Engelman A and Craigie R (1995) Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity. J Virol 69:5908-5911.
18. Esposito D and Craigie R (1998) Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. Embo Journal 17:5832-5843.
19. Farnet CM and Haseltine WA (1991) Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 65:1910-1915.
20. Foloppe N and MacKerell ADJ (2000) All-Atom Empirical Force Field for Nucleic Acids: I. Parameter Optimization Based on Small Molecule and Condensed Phase Macromolecular Target Data. J Comput Chem 21:86-102.
21. Gao K, Butler SL, and Bushman F (2001) Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. EMBO (Eur Mol Biol Organ) J 20:3565-3576.
22. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, and Davies DR (1999) Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 96:13040-13043.
23. Goldgur Y, Dyda F, Hickman AB, Jenkins TM, Craigie R, and Davies DR (1998) Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci USA 95:9150-9154.
24. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J, et al. (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 99:6661-6666.
25. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espesath A, Gabryelski L, Schlelf W, Blau C, et al. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (Wash DC) 287:646-650.
26. Hazuda DJ, Wolfe AL, Hastings JC, Robbins HL, Graham PL, LaFemina RL, and Emini EA (1994) Viral long terminal repeat substrate binding characteristics of the human immunodeficiency virus type 1 integrase. J Biol Chem 269:3999-4004.
27. Heuer TS and Brown PO (1998) Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry 37:6667-6678.
28. Jenkins TM, Engelman A, Ghirlando R, and Craigie R (1996) A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem 271:7712-7718.
29. Johnson AA, Marchand C, and Pommier Y (2003) HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem, in press.
30. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, and Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926-935.
31. Jorgensen WL, Maxwell DS, and Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236.
32. Karki RG, Tang Y, and Nicklaus M (2002) Model of the HIV-1 Integrase-viral DNA complex - a template for structure-based design of HIV integrase inhibitors, in Proceedings of the 223rd National Meeting of the American Chemical Society; 2002 Apr 7-11; Orlando, FL.
33. King PJ, Lee DJ, Reinke RA, Victoria JG, Beale K, and Robinson WE Jr (2003) Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology 306:147-161.
34. 2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase. Biochemistry 39:9285-9294.
35. Lodi PJ, Ernst JA, Kuszewski J, Hickman AB, Engelman A, Craigie R, Clore GM, and Gronenborn AM (1995) Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 34:9826-9833.
36. MacKerell AD Jr, Bashford D, Bellott M, Dunbrack RL Jr, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102:3586-3616.
37. Maignan S, Guilloteau JP, Zhou-Liu Q, Clement-Mella C, and Mikol V (1998) Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol 282:359-368.
38. Marchand C, Neamati N, and Pommier Y (2001) In vitro human immunodeficiency virus type 1 integrase assays. Methods Enzymol 340:624-633.
39. Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR Jr, and Pommier Y (2002) Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem 277:12596-12603.
40. Miller MD, Farnet CM, and Bushman FD (1997) Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 71:5382-5390.
41. Neamati N (2002) Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. Expert Opin Ther Patents 12:709-724.
42. Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y, et al. (2002) Structure activity of 3-aryl-1, 3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem 45:3184-3194.
43. Podtelezhnikov AA, Gao K, Bushman FD, and McCammon JA (2003) Modeling HIV-1 integrase complexes based on their hydrodynamic properties. Biopolymers 68:110-120.
44. Pommier Y, Pilon AA, Bajaj K, Mazumder A, and Neamati N (1997) HIV-1 integrase as a target for antiviral drugs. Antiviral Chem Chemother 8:463-483.
45. Priet S, Navarro JM, Querat G, and Sire J (2003) Reversion of the lethal phenotype of an HIV-1 integrase mutant virus by overexpression of the same integrase mutant protein. J Biol Chem
46. Richman DD (2001) HIV chemotherapy. Nature (Lond) 410:995-1001.
47. Singh SB, Zink DL, Bills GF, Teran A, Silverman KC, Lingham RB, Felock P, and Hazuda DJ (2003a) Four novel bis-(naphtho-gamma-pyrones) isolated from Fusarium species as inhibitors of HIV-1 integrase. Bioorg Med Chem Lett 13:713-717.
48. Singh SB, Zink DL, Dombrowski AW, Polishook JD, Ondeyka JG, Hirshfield J, Felock P, and Hazuda DJ (2003b) Integracides: tetracyclic triterpenoid inhibitors of HIV-1 integrase produced by Fusarium sp. Bioorg Med Chem 11:1577-1582.
49. Skalka AM (1999) Retroviral Integration. Academic Press, San Diego.
50. Sotriffer CA, Ni H, and McCammon JA (2000a) Active site binding modes of HIV-1 integrase inhibitors. J Med Chem 43:4109-4117.
51. Sotriffer CA, Ni H, and McCammon JA (2000b) HIV-1 integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. J Am Chem Soc 122:6136-6137.
52. Wang JY, Ling H, Yang W, and Craigie R (2001) Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO (Eur Mol Biol Organ) J 20:7333-7343.
53. Witvrouw M, Fikkert V, Van Maele B, Pannecouque C, Neamati N, Burke TR, Pais G, De Clercq E, and Debyser Z (2002) Antiviral resistance to diketo acids is associated with mutations T66I, L74M and S230R in the HIV integrase Gene presented at the 15th International Conference on Antiviral Research, Prague, Czech Republic. Antiviral Res 53:A18.
54. Yoshinaga T, Fujishita T, and Fujiwara T (2002) In vitro activity of new HIV-1 integrase inhibitors in clinical development, in 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle, WA.
55. Young SD and the HIV integrase inhibitor discovery team (2002) L-870,810: A potent antiviral HIV integrase inhibitor with potential clinical utility XIV International AIDS Conference; 2002 Jul 7-12; Barcelona, Spain.
56. Zagarian L, Benleulmi MS, Renisio JG, Merad H, Maroun RG, Wieber F, Mauffret O, Porumb H, Troalen F, and Fermandjian S (2003) Strategy to discriminate between high and low affinity bindings of human immunodeficiency virus, type 1 integrase to viral DNA. J Biol Chem 278:19966-19973.
57. Zhang X, Pais GC, Svarovskaia ES, Marchand C, Johnson AA, Karki RG, Nicklaus MC, Pathak VK, Pommier Y, and Burke TR (2003) Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors. Bioorg Med Chem Lett 13:1215-1219.
58. Zhao L, O'Reilly MK, Shultz MD, and Chmielewski J (2003) Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. Bioorg Med Chem Lett 13:1175-1177.
59. Zhuang L, Wai JS, Embrey MW, Fisher TE, Egbertson MS, Payne LS, Guare JP Jr, Vacca JP, Hazuda DJ, Felock PJ, et al. (2003) Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem 46:453-456.